Fulcrum Therapeutics (FULC) 10% Owner Kevin Tang Buys Shares

What Happened
Kevin Tang, a reported 10% owner of Fulcrum Therapeutics (FULC), purchased a total of 249,946 shares in open-market/private purchases between July 13–15, 2026. The filing breaks the buys into four line items: 12,966 shares at $3.54 ($45,900) on 7/13; 53,651 shares at $3.56 ($190,998) on 7/14; 75,952 shares at $3.58 ($271,908) on 7/14; and 107,377 shares at $3.56 ($382,262) on 7/15. Aggregate cash outlay across these transactions is about $891,068. These are purchases (transaction code P), which are generally considered a more informative/bullish signal than routine sales.

Key Details

• Transaction dates: July 13, July 14 (two purchases), and July 15, 2026. All reported on Form 4 filed July 15, 2026. Filing appears timely.
• Reported prices: weighted-average prices reported; individual trades occurred across roughly $3.50–$3.60 per share (footnotes specify narrower ranges by line item, e.g., $3.54–$3.55 for one lot).
• Shares acquired: 249,946 total; total value ≈ $891,068.
• Beneficial ownership note: Footnote indicates Tang beneficially owns shares through Tang Capital entities (TCP, TCPI, TCP III, TCP IV), which together are listed as owning 6,913,329 shares.
• Transaction type: Open market or private purchases (code P). No derivatives, option exercises, gifts, or tax-withholding involved in these line items.
• Footnotes: Weighted-average pricing and multi-trade ranges provided; reporting person offers to supply trade-by-trade detail on request.

Context
Kevin Tang is a 10% owner acting through investment vehicles (institutional-style ownership), not an ordinary employee equity grant. Purchases by large shareholders can signal additional stake-building but are not direct evidence of future company performance. The filing is factual disclosure of purchases and does not state motivation.